XML 61 R32.htm IDEA: XBRL DOCUMENT
v3.24.1

Group Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Interests In Other Entities [Abstract] |
Summary of Information about Subsidiaries | The consolidated financial statements include the following subsidiaries:
|  |  |  |  | % equity interest
Name | Country of incorporation | Registered office |  |  | December 31, 2023 | December 31, 2022
BioNTech BioNTainer Holding GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Cell & Gene Therapies GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Delivery Technologies GmbH | Germany | Halle |  |  | 100 | % | 100 | %
BioNTech Diagnostics GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Europe GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Idar-Oberstein Services GmbH | Germany | Idar-Oberstein |  |  | 100 | % | 100 | %
BioNTech Individualized mRNA Manufacturing GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Innovation and Services Marburg GmbH | Germany | Marburg |  |  | 100 | % | 100 | %
BioNTech Innovation GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Innovative Manufacturing Services GmbH | Germany | Idar-Oberstein |  |  | 100 | % | 100 | %
BioNTech Manufacturing GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Manufacturing Marburg GmbH | Germany | Marburg |  |  | 100 | % | 100 | %
BioNTech Real Estate Holding GmbH | Germany | Holzkirchen |  |  | 100 | % | 100 | %
BioNTech Real Estate Verwaltungs GmbH | Germany | Holzkirchen |  |  | 100 | % | 100 | %
InstaDeep DE GmbH | Germany | Berlin |  |  | 100 | % | n/a(2)
JPT Peptide Technologies GmbH | Germany | Berlin |  |  | 100 | % | 100 | %
NT Security and Services GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
reSano GmbH | Germany | Mainz |  |  | 100 | % | 100 | %
BioNTech Australia Pty Ltd. | Australia | Melbourne |  |  | 100 | % | 100 | %
BioNTech R&D (Austria) GmbH | Austria | Vienna |  |  | 100 | % | 100 | %
BioNTech (Shanghai) Pharmaceuticals Co. Ltd. | China | Shanghai |  |  | 100 | % | 100 | %
InstaDeep France SAS | France | Paris |  |  | 100 | % | n/a(2)
Biopharma BioNTech Israel Ltd. | Israel | Tel Aviv |  |  | 100 | % | n/a(1)
New Technologies Re | Luxembourg | Luxembourg |  |  | 100 | % | n/a(1)
InstaDeep Nigeria Limited | Nigeria | Lagos |  |  | 100 | % | n/a(2)
BioNTech Rwanda Ltd. | Rwanda | Kigali |  |  | 100 | % | 100 | %
BioNTech Sénégal Suarl | Senegal | Dakar |  |  | 100 | % | n/a(1)
BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. | Singapore | Singapore |  |  | 100 | % | 100 | %
BioNTech Pharmaceuticals Spain S.L | Spain | Barcelona |  |  | 100 | % | n/a(1)
BioNTech Switzerland GmbH | Switzerland | Basel |  |  | 100 | % | n/a(1)
BioNTech Taiwan Co. Ltd. | Taiwan | Taipei |  |  | 100 | % | n/a(1)
InstaDeep Tunisia SARL | Tunisia | Tunis |  |  | 100 | % | n/a(2)
BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi | Türkiye | Istanbul |  |  | 100 | % | 100 | %
BioNTech UK Ltd. | United Kingdom | London |  |  | 100 | % | 100 | %
InstaDeep Ltd. | United Kingdom | London |  |  | 100 | % | 5.3%(2)
BioNTech Research and Development, Inc. | United States | Cambridge |  |  | 100 | % | 100 | %
BioNTech USA Holding, LLC | United States | Cambridge |  |  | 100 | % | 100 | %
BioNTech US Inc. | United States | Cambridge |  |  | 100 | % | 100 | %
BioNTech Delivery Technologies (US), LLC | United States | Cambridge |  |  | 100 | % | n/a(2)
InstaDeep LLC | United States | Dover |  |  | 100 | % | n/a(2)
JPT Peptide Technologies Inc. | United States | Cambridge |  |  | 100 | % | 100 | %
(1) Included during the year ended December 31, 2023. (2) Fully acquired during the year ended December 31, 2023.
Summary of Information about Parent Company | ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM.
|  |  |  |  | Ownership of ordinary shares in BioNTech (in %)
Name | Country of incorporation | Registered office |  |  | December 31, 2023 | December 31, 2022
AT Impf GmbH | Germany | Munich |  |  | 43.77 | % | 43.42 | %
Summary of Information about Entity with Significant Influence Over Group | Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated:
|  |  |  |  | Ownership of ordinary shares in BioNTech (in %)
Name | Country of incorporation | Registered office |  |  | December 31, 2023 | December 31, 2022
Medine GmbH | Germany | Mainz |  |  | 17.01 | % | 17.38 | %

X
- Definition Disclosure Of Entity With Significant Influence Over Group Explanatory + References No definition available. + Details
Name: | bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock
Namespace Prefix: | bntx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Significant Investments By Parent Company Explanatory + References No definition available. + Details
Name: | bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock
Namespace Prefix: | bntx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | bntx_InterestsInOtherEntitiesAbstract
Namespace Prefix: | bntx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration